Historical performance in the Oncology category.
Source: Acquire.fyi, Jan 1, 2025 - Jul 13, 2026.
Largest mergers and acquisitions by disclosed deal value.
| Acquirer | Target | Type | Value | Headline |
|---|---|---|---|---|
| Gilead Sciences | Arcellx | Acquisition | $7.6B | Gilead Sciences acquires Arcellx in $7,589.0M deal |
| Novartis | Myricx Bio | Acquisition | $1.5B | Novartis Bets $1.5 Billion on Myricx ADC Payload Platform |
| Tempus AI, Inc. | Paige | Acquisition | $81.3M | Tempus AI, Inc. acquires Paige in $81.3M predominantly in tempus common stock deal |
| AstraZeneca | Modella AI | Acquisition | Undisclosed | AstraZeneca acquires Modella AI |
| SeqOne | Congenica | Acquisition | Undisclosed | SeqOne to acquire Congenica |
Page 1 of latest articles and deal coverage.
The deal gives Novartis a differentiated antibody drug conjugate engine as large pharma races to secure better-tolerated oncology assets before clinical validation drives prices higher.